10-1074-LS
- Generic Name
- 10-1074-LS
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 77
- Registration Number
- NCT03554408
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
3BNC117 and 10-1074 in ART-treated Individuals
Phase 1
Completed
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 26
- Registration Number
- NCT03526848
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, United States
3BNC117 and 10-1074 in HIV-infected Individuals
Phase 1
Completed
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 34
- Registration Number
- NCT02825797
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
🇺🇸The Rockefeller University, New York, New York, United States
3BNC117 and 10-1074 in HIV Uninfected Adults
Phase 1
Completed
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 24
- Registration Number
- NCT02824536
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath